Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 10, 2014, Pages 1706-1716

  Siefert, S A ^a   Chabasse, C ^a   Mukhopadhyay, S ^a   Hoofnagle, M H ^a   Strickland, D K ^a   Sarkar, R ^a   Antalis, T M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Plasminogen activator inhibitor 1; Plasminogen activator inhibitor 2; Serine protease inhibitors; Serine proteases; Urokinase type plasminogen activator; Venous thrombosis

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GELATINASE A; GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE; MMP2 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ENZYME ACTIVITY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; MACROPHAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBUS; WILD TYPE; ANIMAL; C57BL MOUSE; CROSS BREEDING; CYTOLOGY; DNA MICROARRAY; GENETICS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; METABOLISM; NEUTROPHIL; PHYSIOLOGY; THROMBOSIS; TRANSGENIC MOUSE; VENOUS THROMBOSIS;

ANIMALS; CROSSES, GENETIC; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUTROPHILS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; THROMBOSIS; VENOUS THROMBOSIS;

EID: 84907887447     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12657     Document Type: Article

References (51)

1. Moll S, Mackman N. Venous thromboembolism: a need for more public awareness and research into mechanisms. Arterioscler Thromb Vasc Biol 2008; 28: 367-9.
2. Henke PK, Wakefield T. Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes. Thromb Res 2009; 123 (Suppl. 4): S72-8.
3. Meissner MH, Caps MT, Zierler BK, Polissar N, Bergelin RO, Manzo RA, Strandness DE Jr. Determinants of chronic venous disease after acute deep venous thrombosis. J Vasc Surg 1998; 28: 826-33.
4. Saha P, Humphries J, Modarai B, Mattock K, Waltham M, Evans CE, Ahmad A, Patel AS, Premaratne S, Lyons OT, Smith A. Leukocytes and the natural history of deep vein thrombosis: current concepts and future directions. Arterioscler Thromb Vasc Biol 2011; 31: 506-12.
5. Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol 2008; 28: 387-91.
6. Henke PK, Pearce CG, Moaveni DM, Moore AJ, Lynch EM, Longo C, Varma M, Dewyer NA, Deatrick KB, Upchurch GR Jr, Wakefield TW, Hogaboam C, Kunkel SL. Targeted deletion of CCR2 impairs deep vein thombosis resolution in a mouse model. J Immunol 2006; 177: 3388-97.
7. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
8. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005; 93: 647-54.
9. Northeast AD, Soo KS, Bobrow LG, Gaffney PJ, Burnand KG. The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus. J Vasc Surg 1995; 22: 573-9.
10. Singh I, Burnand KG, Collins M, Luttun A, Collen D, Boelhouwer B, Smith A. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 2003; 107: 869-75.
11. Gossage JA, Humphries J, Modarai B, Burnand KG, Smith A. Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution. J Vasc Surg 2006; 44: 1085-90.
12. Humphries J, Gossage JA, Modarai B, Burnand KG, Sisson TH, Murdoch C, Smith A. Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis. J Vasc Surg 2009; 50: 1127-34.
13. Gettins PG. Serpin structure, mechanism, and function. Chem Rev 2002; 102: 4751-804.
14. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 1879-83.
15. Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) 1985; 290: 1453-6.
16. Bern MM, McCarthy N. Failure to lyse venous thrombi because of elevated plasminogen activator Inhibitor 1 (PAI-1) and 4G polymorphism of its promotor genome (The PAI-1/4G Syndrome). Clin Appl Thromb Hemost 2010; 16: 574-8.
17. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-6.
18. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-60.
19. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 2000; 95: 577-80.
20. Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, Vlasuk GP, Gardell SJ, Crandall DL. Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost 2008; 6: 1558-64.
21. Diaz JA, Ballard-Lipka NE, Farris DM, Hawley AE, Wrobleski SK, Myers DD, Henke PK, Lawrence DA, Wakefield TW. Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg 2012; 55: 815-22.
22. Diaz JA, Hawley AE, Alvarado CM, Berguer AM, Baker NK, Wrobleski SK, Wakefield TW, Lucchesi BR, Myers DD Jr. Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model. Thromb Haemost 2010; 104: 366-75.
23. Harbour JW, Dean DC. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2000; 2: E65-7.
24. Mikus P, Urano T, Liljestrom P, Ny T. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. Eur J Biochem 1993; 218: 1071-82.
25. Ye RD, Wun TC, Sadler JE. Mammalian protein secretion without signal peptide removal. Biosynthesis of plasminogen activator inhibitor-2 in U-937 cells. J Biol Chem 1988; 263: 4869-75.
26. Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69: 460-6.
27. Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-24.
28. Schroder WA, Gardner J, Le TT, Duke M, Burke ML, Jones MK, McManus DP, Suhrbier A. SerpinB2 deficiency modulates Th1Th2 responses after schistosome infection. Parasite Immunol 2010; 32: 764-8.
29. Schroder WA, Le TT, Major L, Street S, Gardner J, Lambley E, Markey K, MacDonald KP, Fish RJ, Thomas R, Suhrbier A. A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity. J Immunol 2010; 184: 2663-70.
30. Darnell GA, Schroder WA, Gardner J, Harrich D, Yu H, Medcalf RL, Warrilow D, Antalis TM, Sonza S, Suhrbier A. SerpinB2 is an inducible host factor involved in enhancing HIV-1 transcription and replication. J Biol Chem 2006; 281: 31348-58.
31. Zhao A, Yang Z, Sun R, Grinchuk V, Netzel-Arnett S, Anglin IE, Driesbaugh KH, Notari L, Bohl JA, Madden KB, Urban JF Jr, Antalis TM, Shea-Donohue T. SerpinB2 is critical to Th2 immunity against enteric nematode infection. J Immunol 2013; 190: 5779-87.
32. Dougherty KM, Pearson JM, Yang AY, Westrick RJ, Baker MS, Ginsburg D. The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc Natl Acad Sci U S A 1999; 96: 686-91.
33. Medcalf RL. Plasminogen activator inhibitor type 2: still an enigmatic serpin but a model for gene regulation. Methods Enzymol 2011; 499: 105-34.
34. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao-Pick TP, Pantoja C, Erle DJ, Yamamoto KR, Fahy JV. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A 2007; 104: 15858-63.
35. Palafox-Sanchez CA, Vazquez-Del Mercado M, Orozco-Barocio G, Garcia-De la Torre I, Torres-Carrillo N, Torres-Carrillo NM, Illades-Aguiar B, Munoz-Valle JF. A functional Ser(413)/Ser(413) PAI-2 polymorphism is associated with susceptibility and damage index score in systemic lupus erythematosus. Clin Appl Thromb Hemost 2009; 15: 233-238.
36. Vazquez-Del Mercado M, Garcia-Cobian TA, Munoz Valle JF, Torres-Carrillo N, Martin-Marquez BT, Arana-Argaez VE, Best-Aguilera CR, Martinez-Garcia EA, Petri MH, Nunez-Atahualpa L, Delgado-Rizo V. Genotype Ser413/Ser of PAI-2 polymorphism Ser413/Cys is associated with anti-phospholipid syndrome and systemic lupus erythematosus in a familial case: comparison with healthy controls. Scand J Rheumatol 2007; 36: 206-210.
37. Day SM, Reeve JL, Myers DD, Fay WP. Murine thrombosis models. Thromb Haemost 2004; 92: 486-94.
38. Dahi S, Lee JG, Lovett DH, Sarkar R. Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin. J Vasc Surg 2005; 42: 539-45.
39. McGilvray KC, Sarkar R, Nguyen K, Puttlitz CM. A biomechanical analysis of venous tissue in its normal and post-phlebitic conditions. J Biomech 2010; 43: 2941-7.
40. Abramoff MD, Magalhaes PJ, Ram SJ. Image processing with Image. J Biophotonics Int 2004; 11: 36-42.
41. Deatrick KB, Eliason JL, Lynch EM, Moore AJ, Dewyer NA, Varma MR, Pearce CG, Upchurch GR, Wakefield TW, Henke PK. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg 2005; 42: 140-8.
42. Sood V, Luke C, Miller E, Mitsuya M, Upchurch GR Jr, Wakefield TW, Myers DD, Henke PK. Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline. Ann Vasc Surg 2010; 24: 233-41.
43. Varma MR, Varga AJ, Knipp BS, Sukheepod P, Upchurch GR, Kunkel SL, Wakefield TW, Henke PK. Neutropenia impairs venous thrombosis resolution in the rat. J Vasc Surg 2003; 38: 1090-8.
44. Ritchie H, Jamieson A, Booth NA. Thrombin modulates synthesis of plasminogen activator inhibitor type 2 by human peripheral blood monocytes. Blood 1995; 86: 3428-35.
45. Park JM, Greten FR, Wong A, Westrick RJ, Arthur JS, Otsu K, Hoffmann A, Montminy M, Karin M. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis-CREB and NF-kappaB as key regulators. Immunity 2005; 23: 319-29.
46. Ritchie H, Robbie LA, Kinghorn S, Exley R, Booth NA. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin. Thromb Haemost 1999; 81: 96-103.
47. Henke PK, Varma MR, Deatrick KB, Dewyer NA, Lynch EM, Moore AJ, Dubay DA, Sukheepod P, Pearce CG, Upchurch GR Jr, Kunkel SL, Franz MG, Wakefield TW. Neutrophils modulate post-thrombotic vein wall remodeling but not thrombus neovascularization. Thromb Haemost 2006; 95: 272-81.
48. Baldwin JF, Sood V, Elfline MA, Luke CE, Dewyer NA, Diaz JA, Myers DD, Wakefield T, Henke PK. The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. J Vasc Surg 2012; 56: 1089-97.
49. Cao C, Lawrence DA, Li Y, von Arnim CA, Herz J, Su EJ, Makarova A, Hyman BT, Strickland DK, Zhang L. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J 2006; 25: 1860-70.
50. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1563-71.
51. Henke PK, Varga A, De S, Deatrick CB, Eliason J, Arenberg DA, Sukheepod P, Thanaporn P, Kunkel SL, Upchurch GR Jr, Wakefield TW. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. Arterioscler Thromb Vasc Biol 2004; 24: 1130-7.